Imagion Biosystems (ASX: IBX) is at a pivotal point of its history, about to take its MagSense technology into Phase 2.
Abstract: MagSense is a better solution
MagSense is a first-of-its-kind imaging agent with potential to diagnose cancers – starting with HER2 breast cancer. Compared to other agents it has the potential to be safer and better at identifying cancers at an earlier stage, which for patients can mean intervention is cheaper, less invasive and more likely to succeed. It is also less invasive and painful then mechanisms such as biopsies. MagSense works seamlessly with existing MRI scanners and clinical workflows and has a capital-light business model.
